169 related articles for article (PubMed ID: 27479790)
1. Radiopharmaceuticals for somatostatin receptor imaging.
Mikołajczak R; Maecke HR
Nucl Med Rev Cent East Eur; 2016; 19(2):126-32. PubMed ID: 27479790
[TBL] [Abstract][Full Text] [Related]
2. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT.
Madrzak D; Mikołajczak R; Kamiński G
Nucl Med Rev Cent East Eur; 2016; 19(2):88-92. PubMed ID: 27479886
[TBL] [Abstract][Full Text] [Related]
3. Radiolabeled bicyclic somatostatin-based analogs: a novel class of potential radiotracers for SPECT/PET of neuroendocrine tumors.
Fani M; Mueller A; Tamma ML; Nicolas G; Rink HR; Cescato R; Reubi JC; Maecke HR
J Nucl Med; 2010 Nov; 51(11):1771-9. PubMed ID: 20956465
[TBL] [Abstract][Full Text] [Related]
4. NEN - the role of somatostatin receptor scintigraphy in clinical setting.
Opalińska M; Hubalewska-Dydejczyk A; Sowa-Staszczak A; Stefańska A
Nucl Med Rev Cent East Eur; 2016; 19(2):118-25. PubMed ID: 27479789
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
[TBL] [Abstract][Full Text] [Related]
6. PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature.
Johnbeck CB; Knigge U; Kjær A
Future Oncol; 2014 Nov; 10(14):2259-77. PubMed ID: 25471038
[TBL] [Abstract][Full Text] [Related]
7. New trends in peptide receptor radioligands.
Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Andreae F; Kurtaran A; Dudczak R
Q J Nucl Med; 2001 Jun; 45(2):153-9. PubMed ID: 11476164
[TBL] [Abstract][Full Text] [Related]
8. New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy.
Virgolini I; Traub T; Leimer M; Novotny C; Pangerl T; Ofluoglu S; Halvadjieva E; Smith-Jones P; Flores J; Li SR; Angelberger P; Havlik E; Andreae F; Raderer M; Kurtaran A; Niederle B; Dudczak R
Q J Nucl Med; 2000 Mar; 44(1):50-8. PubMed ID: 10932601
[TBL] [Abstract][Full Text] [Related]
9. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors.
Ginj M; Zhang H; Waser B; Cescato R; Wild D; Wang X; Erchegyi J; Rivier J; Mäcke HR; Reubi JC
Proc Natl Acad Sci U S A; 2006 Oct; 103(44):16436-41. PubMed ID: 17056720
[TBL] [Abstract][Full Text] [Related]
10.
Hope TA; Calais J; Zhang L; Dieckmann W; Millo C
J Nucl Med; 2019 Sep; 60(9):1266-1269. PubMed ID: 30850506
[TBL] [Abstract][Full Text] [Related]
11. Comparative somatostatin receptor scintigraphy using in-111-DOTA-lanreotide and in-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy.
Virgolini I; Patri P; Novotny C; Traub T; Leimer M; Füger B; Li SR; Angelberger P; Raderer M; Wogritsch S; Kurtaran A; Kletter K; Dudczak R
Ann Oncol; 2001; 12 Suppl 2():S41-5. PubMed ID: 11762351
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin analogs and radiopeptides in cancer therapy.
Froidevaux S; Eberle AN
Biopolymers; 2002; 66(3):161-83. PubMed ID: 12385036
[TBL] [Abstract][Full Text] [Related]
13. Radio-guided surgery in neuroendocrine tumors.
Gulec SA; Baum R
J Surg Oncol; 2007 Sep; 96(4):309-15. PubMed ID: 17726664
[TBL] [Abstract][Full Text] [Related]
14. Tumor imaging and therapy using radiolabeled somatostatin analogues.
de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin Receptor Antagonists for Imaging and Therapy.
Fani M; Nicolas GP; Wild D
J Nucl Med; 2017 Sep; 58(Suppl 2):61S-66S. PubMed ID: 28864614
[TBL] [Abstract][Full Text] [Related]
16. Imaging of neuroendocrine tumours with gamma-emitting radiopharmaceuticals.
Bombardieri E; Coliva A; Maccauro M; Seregni E; Orunesu E; Chiti A; Lucignani G
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):3-15. PubMed ID: 20168282
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic applications of radiolabeled peptides in nuclear endocrinology.
Behr TM; Béhé M; Becker W
Q J Nucl Med; 1999 Sep; 43(3):268-80. PubMed ID: 10568142
[TBL] [Abstract][Full Text] [Related]
18. In Vivo Evaluation of ¹⁸F-SiFAlin-Modified TATE: A Potential Challenge for ⁶⁸Ga-DOTATATE, the Clinical Gold Standard for Somatostatin Receptor Imaging with PET.
Niedermoser S; Chin J; Wängler C; Kostikov A; Bernard-Gauthier V; Vogler N; Soucy JP; McEwan AJ; Schirrmacher R; Wängler B
J Nucl Med; 2015 Jul; 56(7):1100-5. PubMed ID: 25977461
[TBL] [Abstract][Full Text] [Related]
19. 99mTc-N4-[Tyr3]Octreotate Versus 99mTc-EDDA/HYNIC-[Tyr3]Octreotide: an intrapatient comparison of two novel Technetium-99m labeled tracers for somatostatin receptor scintigraphy.
Gabriel M; Decristoforo C; Maina T; Nock B; vonGuggenberg E; Cordopatis P; Moncayo R
Cancer Biother Radiopharm; 2004 Feb; 19(1):73-9. PubMed ID: 15068614
[TBL] [Abstract][Full Text] [Related]
20. Radiolabeled peptides in diagnosis and tumor imaging: clinical overview.
Warner RR; O'dorisio TM
Semin Nucl Med; 2002 Apr; 32(2):79-83. PubMed ID: 11965602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
